{"database": "lobbying", "table": "lobbying_activities", "rows": [[1581428, "bbd97b32-5ae4-430c-8c0b-33bfae5290ab", "Q3", "CSL BEHRING LLC", 308935, "CSL BEHRING LLC", 2014, "third_quarter", "HCR", "Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee.\n\nOrphan designation - the need to delink clinical superiority from designation\n\nPreservation of the Orphan Drug Tax Credit", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, 170000, 0, 0, "2014-10-01T15:57:12.257000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1581428"], "units": {}, "query_ms": 12.299922993406653, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}